Heart failure with reduced ejection fraction (HFrEF) and diabetes are two interconnected health conditions that significantly impact the quality of life for many individuals. Managing these conditions often requires innovative approaches to improve heart function, regulate blood sugar levels, and optimize energy usage in the body. This study focuses on SGLT2 inhibitors, a type of medication originally designed to help control blood sugar in people with diabetes. Researchers are now investigating how this medication might also benefit heart health by influencing certain energy-related molecules and improving heart function.

The study will track changes in key indicators, including the levels of specific energy markers called plasma ketones (β-hydroxybutyrate and acetoacetate), both at the beginning and end of the study. Researchers will also monitor improvements in how well the heart pumps and relaxes, known as systolic and diastolic function, as well as overall blood sugar control. Toward the end of the study, they aim to observe whether the medication reduces plasma ketone levels, providing further insight into its effects on heart and metabolic health. By understanding these mechanisms, the study could pave the way for more effective treatments for patients managing both diabetes and heart failure.